文献速递瓣膜外科冠心病外科

既往乳内动脉桥通畅患者的小切口主动脉瓣手术

Ministernotomy aortic valve surgery in patients with prior patent mammary artery grafts after coronary artery bypass grafting.
PubMed 文献 · Eur J Cardiothorac Surg · 2019-01-01

本研究回顾了48例既往CABG后存在至少1根通畅原位乳内动脉桥、接受微创主动脉瓣置换患者的短长期结局。采用经右颈内静脉逆行心麻液灌注联合顺行灌注及中低温、不阻断乳内动脉桥的策略,30天死亡率为4%,无中转全胸骨切开。该策略安全可靠,结合微创入路可减少手术创伤。

要点

  • 术前CT评估通畅桥血管与胸骨关系,经右颈内静脉置入逆行灌注和肺 vent 导管。
  • 不阻断原位乳内动脉桥,采用横主动脉切口避开桥血管开口暴露主动脉瓣。
  • 中低温28-30°C联合顺行诱导和连续逆行冷血心麻液灌注是安全策略。

核心结论

  • 经皮逆行心麻液联合顺行心麻液和中低温、不中断乳内动脉桥血流,是通畅乳内动脉桥患者行主动脉瓣置换的安全可靠策略。

研究设计与样本

  • 2008至2016年单中心回顾性研究,纳入48例既往CABG后至少1根通畅原位乳内动脉桥并接受微创主动脉瓣置换的患者。

主要发现

  • 中位体外循环时间和主动脉阻断时间分别为124分钟(Q1-Q3:108-164)和92分钟(Q1-Q3:83-116)。
  • 30天死亡率为4%(2/48),无中转全胸骨切开,无因术后出血或胸骨伤口感染再手术。
  • 排除2例院内死亡患者后,中位术后住院时间为7天(Q1-Q3:5-8)。
  • 1年、5年和10年总生存率分别为94%、87%和44%。

临床怎么用

  • 对既往CABG后存在通畅乳内动脉桥需行主动脉瓣置换的患者,可考虑微创入路联合逆行心麻液灌注且不阻断桥血管。
  • 术前CT评估桥血管与胸骨关系,经右颈内静脉置入逆行灌注导管,术中采用横主动脉切口避开桥血管开口。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Patients with patent internal thoracic artery (ITA) grafts after prior coronary artery bypass grafting surgery who require aortic valve replacement (AVR) pose unique technical challenges for safe and optimal myocardial protection. The purpose of this study is to review our short- and long-term outcomes with redo minimally invasive AVR in patients with patent in situ ITA grafts. METHODS: From 2008 to 2016, 48 patients with at least 1 patent in situ mammary artery graft underwent minimally invasive AVR. Preoperative computed tomography was performed in all patients to evaluate the relationship of patent grafts to the sternum. Retrograde coronary sinus and pulmonary vent catheters were placed via the right internal jugular vein. The in situ ITA grafts were not clamped during AVR. Transverse aortotomy, taking care to avoid the grafts arising from the aorta, was performed to expose the aortic valve. RESULTS: The median age of the patients was 78 years [Quartile 1 (Q1)-Quartile 3 (Q3): 71-81]. Thirty-nine (81%) patients were men, and 46 (96%) patients had aortic stenosis. The median cardiopulmonary bypass and cross-clamp times were 124 (Q1-Q3: 108-164) and 92 (Q1-Q3: 83-116) min, respectively. Moderate hypothermia at 28-30°C was used in all patients. Most patients received cold blood cardioplegia with antegrade induction and continuous retrograde delivery. Four patients received only retrograde delivery due to some degree of aortic insufficiency. Thirty-day mortality was 4% (2 of 48 patients). There was no conversion to full sternotomy, and no reoperations were performed for postoperative bleeding or sternal wound infection. Excluding the 2 patients who died in the hospital, the median postoperative length of stay was 7 days (Q1-Q3: 5-8). Overall survival at 1, 5 and 10 years was 94%, 87% and 44%, respectively. CONCLUSIONS: Percutaneous retrograde cardioplegia combined with antegrade cardioplegia and moderate hypothermia, without interruption of ITA flow, is a safe and reliable strategy in patients with patent ITA grafts undergoing aortic valve replacement. This strategy combined with a minimally invasive approach may reduce surgical trauma, and is a safe and effective technique in these challenging patients.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Orlov OI, Kaleda VI, Shah VN, et al. Ministernotomy aortic valve surgery in patients with prior patent mammary artery grafts after coronary artery bypass grafting. Eur J Cardiothorac Surg. 2019. PMID: 30649235. doi:10.1093/ejcts/ezy442

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。